

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from Thursday 24th November 2016**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Paul Chatterton – LPC Representative	
Mr Mark Randerson- Head of Medicines Management (NHSD-MMT)	✓	Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓	Dr Eric Dale - Consultant Psychiatrist RDaSH FT		<u>DBHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Ms Anne Burton – Non Medical Prescriber Representative (RDaSH DCIS)	✓	Mr Andrew Barker – Chief Pharmacist DBHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBHFT	✓
Mr Rob Wise – Head of Medicines Management (BCCG)	✓	<u>Doncaster LMC</u>		Dr Mahmoud Al Khoffash – Medical Director representative DBHFT	
		Dr Dean Eggitt- LMC Secretary			
		Mr D Gibbons- LMC Deputy		<u>FCMS (When necessary)</u>	
		Dr Rumit Shah - LMC	✓	Mrs Nicola Sanders	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

Dr Rupert Suckling & Mr Victor Joseph DMBC

Mrs Nicola Sanders & Mrs Tracey Edwards FCMS

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Dr G Payne - Consultant cardiologist (DBHFT)

Agenda Item	Discussion Points	Action By
11/16/1	Apologies Apologies were received from Dr Al Khoffash	
11/16/2	Declarations of Interest, Gifts or Hospitality No declarations were received	
11/16/3	Minutes of last meeting The minutes of the last meeting held on the 27 th October 2016 were agreed as a true and accurate record and will be made available on the medicines management website.	

11/16/4.1	Matters Arising	
11/15/8.4	<p>Potential development of SCP/Pathway update for the management of Adult ADHD</p> <p>RDaSHFT will update the Committee at the January meeting including clarity in the regard of the NICE recommendations to do 3 month monitoring schedule. Clarity will be sought to determine if this would be also applicable for adult patients.</p>	RDaSHFT
08/16/8.1	<p>Bisphosphonate & Breast Cancer Service</p> <p>The LMC confirmed that the discussion with Mrs L Sherburn Head of Partnerships Commissioning regarding the resource implications relating to Primary Care have not been finalised. The decision to adopt the guideline in Doncaster was agreed by the Committee on the basis that delaying this decision would not be in the interest of patients who could benefit from a prompt implementation of this treatment. The Committee accepted that the resource issues will be considered during the next Local Enhanced Services negotiations at the end of the current financial year. The Chair will share this decision with Mrs Sherburn.</p> <p>The points agreed:</p> <ul style="list-style-type: none"> • The guideline will be adopted by Doncaster and will be available on the medicines management website. • Ibandronic Acid 50mg will be categorised as Amber – G (with an off label use). • The CCG will send a letter & the guidance to all Doncaster GP's, signed by Dr Crichton as Chair of the CCG, Dr Pieri as GP Cancer Lead and Dr R Shah on behalf of the LMC. The letter will advise GP's of the guidance and the rationale behind the work. • The unlicensed/off-label medication forms will require agreement at DBHFT. <p>The process for Doncaster can now be completed outside of the APC meeting. Bassetlaw CCG is still in discussion regarding the adoption of the guidance.</p>	<p>NHSD- MMT(AM)</p> <p>DCCG Chair</p> <p>DBHFT</p>
10/16/8.2	<p>Parkinson's Disease SCP</p> <p>RDaSHFT will bring the updated paperwork to the January meeting. It was agreed that Safinamide will be included in the drugs available although will not be used first line.</p> <p>NHSD-MMT will check the Sheffield Traffic Light list for consistency.</p>	<p>RDaSHFT</p> <p>NHSD- MMT(AM)</p>

10/16/17.1	<p>Sacubitril/Valsartan (Entresto) indicated for heart failure The Committee welcomed Dr G Payne Consultant Cardiologist DBHFT to the meeting. The Committee discussed the use of Sacubitril/Valsartan with Dr Payne and the pathway of care for heart failure patients initiated on treatment. The main points made were:</p> <ul style="list-style-type: none"> • Sacubitril/Valsartan will be initiated by either Cardiology (generally in an out-patient clinic) or by the RDASH FT Heart Failure Specialist Nursing Team. • Initially there will be a small numbers of patients due to the indication for use. • The Heart Failure nurses will manage the titration, monitoring, stabilisation and prescribing of the drug. • The drug will be categorised as Amber G, the guidance will include: <ul style="list-style-type: none"> • The first three prescriptions will be provided by the Specialist service • The 4th prescription will be requested from Primary Care, although the patient will not be discharged from the Specialist service for six months or more due to the nature of the condition. • On-going monitoring will include Bloods – U&E’s & LFT’s and be undertaken in Primary Care • Specialist services will ensure that their communication to Primary Care colleagues is clear regarding: <ul style="list-style-type: none"> • advice on ensuring ACE inhibitors or ARBs are not concomitantly prescribed on the patient’s repeat prescription. • Monitoring schedule appropriate to the patient’s clinical condition <p>RDaSHFT will update the Heart Failure Specialist Nurses of the outcome of this meeting NHSD-MMT (GB) will amend the previously suggested guidance to encompass today’s decisions and will liaise with Dr Payne, share with the Chair and Committee before adding to the traffic light comments section. NHSD-MMT (MR) will highlight the cost of the medication to Finance for information. Dr Payne was thanked for attending and then left the meeting.</p>	<p>RDaSHFT NHSD-MMT(GB) NHSD-MMT(MR)</p>
11/16/5	<p>Traffic Light – Drugs for Review All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Cobimetinib (Cotellic) used in melanoma has now been categorised as Grey 2 Levofloxacin (Quinsair nebuliser system) used in cystic fibrosis for chronic pulmonary infections has been categorised as Red 1,2 Ibandronic acid 50mg oral used in breast cancer will be categorised as Amber –G (off-label use), the guidance document will be available on the medicines management website.</p>	<p>NHSD-MMT(AM)</p>

11/16/6	APC Officers actions All officers actions were agreed as proposed and will be updated on the traffic light system.	NHSD- MMT(AM)
11/16/7	Traffic Light – Additions for Consideration All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Reslizumab (Cinqaero) used in asthma has been categorised as Red 1,2	NHSD- MMT(AM)
11/16/8	New Business	
11/16/8.1	Guidance for the Prescribing of Bicalutamide in the treatment of Prostate Cancer (Amber-G) The guidance document is due for review. Mr Leveckis Consultant Urological Surgeon will be asked for comment on the document. The document will return to the Committee for approval once complete.	DBHFT
11/16/8.2	Procedure to request the review of current Doncaster & Bassetlaw APC Traffic Light System (TLS) entries or to submit a consideration for a new entry This document is due for a routine review. The Committee was asked to consider either: <ul style="list-style-type: none"> • Re-authorise the existing document • Approve the shorter version of the document. The Committee agreed to use the new document as it contains all the relevant information with less pages than the original. The medicines management website will be updated with the new document.	NHSD- MMT(AM)
11/16/8.3	Sheffield APC updated SCP (now guidance document) for Denosumab The Committee discussed the updated Sheffield guidance document for Denosumab (formally Shared Care). The Committee highlighted several areas requiring clarification. NHSD-MMT will seek clarification and this item will be discussed again at the January APC meeting.	NHSD- MMT(AM)
11/16/9	DBHFT D&TC Update The minutes of the meeting held in October 2016 were received by the Committee	
11/16/10	Formulary Liaison Group Update The minutes of the meeting held in September 2016 were received by the Committee	
11/16/11	Doncaster Prisons Drug & Therapeutic Committee No minutes available	
11/16/12	RDaSH FT & Medicines Management Committee update The minutes of the meeting held in September 2016 were received by the Committee	
11/16/13	Barnsley Area Prescribing Committee Update The minutes of the meeting held in September & October 2016 were received by the Committee	
11/16/14	Rotherham Area Prescribing Committee update The minutes of the meeting held in August 2016 were received by the Committee	
11/16/15	Sheffield Area Prescribing Committee Update The minutes of the meeting held in September 2016 were	

	received by the Committee	
11/16/16	Nottinghamshire Area Prescribing Committee Update No minutes available	
11/16/17	<p>Any Other Business</p> <ul style="list-style-type: none"> • Antipsychotic clinical management and prescribing pathway. The Committee was updated on the progress of this work. There are on-going meetings to clarify the pathway of care for patients being referred into Secondary Care and also being discharged back into Primary Care. The issue is on the agenda at the Doncaster Clinical Reference Group later today and the safety of the pathway will be discussed. The categorisation of medication on the traffic light system will be considered once the pathway has been agreed. • RDaSHFT informed the Committee that the organisation is investing in the TPP Electronic Patient Record/E Prescribing system. The issue of consent to share information was raised. The Chair confirmed the CCG has recognised that although most TPP GP practices already share a couple have not yet consented to sharing and the reasons for this is being investigated and will hopefully be addressed in the coming months. Further work is also being undertaken through the local digital roadmap work to look at a Doncaster wide solution for sharing patient records. 	
11/16/18	<p>Date, time & venue of next meeting 12 noon prompt Thursday 26th January 2017 in Meeting Room 3 Sovereign House</p>	
	<p>12 noon prompt Thursday 23rd February 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 30th March 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th April 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th May 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th June 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th July 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 31st August 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th September 2017 in Meeting Room 3 Sovereign House</p>	